Affimed ROE 2014-2024 | AFMDQ
Current and historical return on equity (ROE) values for Affimed (AFMDQ) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Affimed ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-09-30 |
$-0.08B |
$0.02B |
-196.18% |
| 2024-06-30 |
$-0.09B |
$0.03B |
-157.47% |
| 2024-03-31 |
$-0.10B |
$0.04B |
-136.91% |
| 2023-12-31 |
$-0.12B |
$0.06B |
-118.56% |
| 2023-09-30 |
$-0.13B |
$0.08B |
-105.35% |
| 2023-06-30 |
$-0.12B |
$0.11B |
-80.68% |
| 2023-03-31 |
$-0.11B |
$0.13B |
-62.76% |
| 2022-12-31 |
$-0.09B |
$0.16B |
-54.12% |
| 2022-09-30 |
$-0.08B |
$0.18B |
-49.41% |
| 2022-06-30 |
$-0.09B |
$0.21B |
-53.05% |
| 2022-03-31 |
$-0.09B |
$0.13B |
-56.24% |
| 2021-12-31 |
$-0.07B |
$0.16B |
-38.58% |
| 2021-09-30 |
$-0.06B |
$0.16B |
-37.70% |
| 2021-06-30 |
$-0.05B |
$0.18B |
-35.18% |
| 2021-03-31 |
$-0.04B |
$0.20B |
-37.31% |
| 2020-12-31 |
$-0.05B |
$0.08B |
-87.04% |
| 2020-09-30 |
$-0.04B |
$0.06B |
-99.44% |
| 2020-06-30 |
$-0.05B |
$0.05B |
-133.33% |
| 2020-03-31 |
$-0.05B |
$0.03B |
-138.13% |
| 2019-12-31 |
$-0.04B |
$0.04B |
-96.73% |
| 2019-09-30 |
$-0.01B |
$0.03B |
-28.03% |
| 2019-06-30 |
$-0.01B |
$0.04B |
-29.89% |
| 2019-03-31 |
$-0.01B |
$0.05B |
-22.80% |
| 2018-12-31 |
$-0.02B |
$0.05B |
-43.40% |
| 2018-09-30 |
$-0.04B |
$0.04B |
-83.58% |
| 2018-06-30 |
$-0.04B |
$0.06B |
-76.38% |
| 2018-03-31 |
$-0.04B |
$0.07B |
-79.14% |
| 2017-12-31 |
$-0.04B |
$0.04B |
-81.87% |
| 2017-09-30 |
$-0.03B |
$0.04B |
-74.16% |
| 2017-06-30 |
$-0.03B |
$0.04B |
-73.12% |
| 2017-03-31 |
$-0.03B |
$0.05B |
-67.66% |
| 2016-12-31 |
$-0.04B |
$0.04B |
-62.50% |
| 2016-09-30 |
$-0.04B |
$0.05B |
-56.25% |
| 2016-06-30 |
$-0.03B |
$0.06B |
-49.25% |
| 2016-03-31 |
$-0.03B |
$0.07B |
-43.48% |
| 2015-12-31 |
$-0.02B |
$0.08B |
-38.82% |
| 2015-09-30 |
$-0.02B |
$0.06B |
-43.14% |
| 2015-06-30 |
$-0.01B |
$0.07B |
-10.31% |
| 2015-03-31 |
$0.02B |
$0.04B |
59.84% |
| 2014-12-31 |
$0.00B |
$0.04B |
0.00% |
| 2014-09-30 |
$-0.01B |
$0.05B |
-72.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.001B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
